Browse our anti-EGFR (EGFR) Antibodies

Horse (Equine) Epidermal Growth Factor Receptor (EGFR) interaction partners

1. Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).

Fruit Fly (Drosophila melanogaster) Epidermal Growth Factor Receptor (EGFR) interaction partners

1. stress-dependent EGFR/MAPK promotes gut regeneration via a novel mechanism that operates independently of Insulin/Pi3K/TOR signaling.

2. EGFR/ARF6 regulation of Hh signaling stimulates oncogenic Ras tumor overgrowth in Drosophila.

3. Graf functions to downregulate EGFR signaling.

4. Data show that EGFR controls the proper formation of brain neuroblasts by regulating the number, survival and proneural gene expression of neuroectodermal progenitor cells which suggest that EGFR signalling is crucially important for patterning and early neurogenesis of the brain.

5. The activity of Gro is antagonized by EGFR signaling, which inhibits Gro-dependent repression via p-ERK mediated phosphorylation.

6. These results reveal that ESCRT-0 (ESCRT-0 components stam and hrs)mutants inhibit EGFR signaling by disrupting Rhomboid endosomal trafficking in the ligand-producing cells.

7. we find that EGFR regulates the apical determinant Crb and the extracellular matrix regulator Serp, two factors previously known to control tube length. EGFR regulates the organisation of endosomes in which Crb and Serp proteins are loaded

8. Here we uncover a cell non-autonomous requirement for the Epidermal growth factor receptor (Egfr) pathway in the lateral epidermis for sustained dpp expression in the LE. Specifically, we demonstrate that Egfr pathway activity in the lateral epidermis prevents expression of the gene scarface (scaf), encoding a secreted antagonist of JNK signaling

9. Loss of Usp5 results in upregulation of Notch signaling and downregulation of RTK signaling by EGF receptor (EGFR) and Sevenless (Sev), leading to impaired photoreceptor development.

10. These data demonstrate a strong genetic link between dG9a and the EGFR signaling pathway.

11. Avermectin directly interacts with EGFR and leads to the activation of the EGFR/AKT/ERK pathway.

12. The dorsoventral patterning and EGFR signaling genes play essential roles in correct identity determination and differentiation of lateral glia in the Drosophila nervous system.

13. Data suggest that OSCP1 (organic solute carrier partner 1) plays multiple roles during eye development in D. melanogaster; OSCP1 regulates developmental gene expression and epidermal growth factor receptor signaling pathway in imaginal discs of eye.

14. The vector of cell movement is regulated by localised epidermal growth factor (EGF) signalling from the distally placed tip cell lineage and the acquisition of planar polarity leads to asymmetric pulsatile Myosin II accumulation.

15. Our findings provide in vivo evidence for the role of adult neurons in the maintenance of glia and a novel role for EGFR signaling in the autophagic flux.

16. Gro inhibits rho expression in undifferentiated cells and represses the expression of both ato and rho in non-R8 precursors during initiation of photoreceptor differentiation in an E(spl)-dependent manner.

17. strategy for producing ordered square cell packing configurations in epithelia and reveal a molecular mechanism by which organized tissue structure is generated through spatiotemporally regulated responses to EGF receptor activation.

18. the findings indicate that Vps4 can promote EGFR activity through an endocytosis-independent mechanism.

19. Drosophila compound eye development is a good model for studying the Egfr signaling pathway.

20. Mechanistically, miR-998 operates by repressing dCbl, a negative regulator of EGFR signaling. Significantly, dCbl is a critical target of miR-998 since dCbl phenocopies the effects of miR-998 on dE2f1-dependent apoptosis in rbf mutants

Zebrafish Epidermal Growth Factor Receptor (EGFR) interaction partners

1. Combination of an EGFR tyrosine kinase inhibitor and a NF-kappaB inhibitor effectively suppressed cetuximab-resistant HNSCC and interfering with the EGFR-LTbeta interaction reverses resistance.

2. Study demonstrated that IGF-I can stimulate egfr expression in both follicles cell culture and intact follicles promoting oocyte maturation.

3. These results indicate that maintenance of Pgrmc1 signaling is required for Egfr expression on zebrafish oocyte cell membranes and for conserving the functions of Egfr in maintaining meiotic arrest through estrogen activation of Gper.

4. EGFR signaling in vertebrate oocytes can prevent meiotic progression.

5. the expression of EGFR was mainly restricted to the follicle cells with little expression in the oocytes

Human Epidermal Growth Factor Receptor (EGFR) interaction partners

1. LRIG1 exerts important tumor-suppressive effects in EGFR-mutant NSCLC.

2. Study showed that a gain of EGFR gene copy number can be observed in 30% of the oral cavity squamous cell carcinoma (OSCC) tumors and this frequency was only slightly increased in tumors from individuals with the CA repeat genotype compared to those with the SS genotype. The EGFR CA repeat polymorphism may play a role synergistically with tumor EGFR expression level in predicting outcome among OSCC patients.

3. these results suggest that sustained presence of lipid inflammatory mediator LTD4 could induce human airway epithelial cell proliferation through ERK1/2 phosphorylation, either directly via CysLT1 receptor or by transactivating EGFR.

4. significant correlation between mutations in exon 19 (rs121913438) and exon 21(rs121434568) and susceptibility to uterine myoma

5. Expression of phospho-EGFR and -Akt as well as the pro-inflammatory molecules TNF-alpha.

6. the results of the present study indicate that, in GBM cells, EGFRvIII is connected with the S1P signaling pathway to enhance cell invasiveness and tumor progression.

7. In this study, we focused on patients with gastric cancer who received preoperative chemotherapy and aimed to examine the changes in HER2 expression status and amplification of EGFR and MET, not only after HER2-targeted therapy, but also after cytotoxic chemotherapy alone.

8. Negative expression of HuR and Bim correlates with lower EGFR-tyrosine kinase inhibitors sensitivity in tumor tissues obtained from EGFR-mutant nonsmall cell lung cancer patients.

9. Combined treatment with NNK and arecoline synergistically facilitated tumor aggressiveness via EGFR-AKT signaling.

10. Co-expression of high levels of beta-catenin and EGFR in association with clinicopathological features implicates their clinical utility in risk stratification of PTC patients, and supports the possibility of crosstalk between Wnt/beta-catenin and EGFR signaling during PTC progression.

11. High EGFR expression is associated with cholangiocarcinoma metastasis.

12. Negative regulation of EGFR signalling by FLCN protein.

13. Our findings also suggest that prostate cancer cells may utilize AR, EGFR and MMP-9 pathways in androgen-dependent as well as in castration-resistant conditions. Our data suggest a new therapeutic potential to block cancer metastasis by targeting AR, EGFR and MMP-9 pathways in subsets of prostate cancer patients.

14. In breast cancer cells, HOXB5 regulates EGFR expression at the transcriptional level by directly binding to its promoter region and promotes phosphorylation of EGFR as well as its downstream effectors.

15. MiR-630 may be a potential biomarker for the prediction of tyrosine kinase inhibitors therapeutic response and outcome in patients with lung adenocarcinoma.

16. High EGFR expression is associated with recurrence of basal cell carcinoma.

17. Data show that Y-box binding protein-1 (YBX1) promoted tumorigenesis and progression in spinal chordoma via the epidermal growth factor receptor (EGFR)/proto-oncogene proteins c-akt (AKT) pathway.

18. Y845 phosphorylation induces a catalytically active conformation in EGFR monomers. This conformational transition depends on EGFR kinase activity and auto-phosphorylation on its C-terminal tail, generating a looped causality that leads to autocatalytic amplification of EGFR phosphorylation at low EGF dose.

19. Studied impact of cumulative smoking dose (CSD) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS), in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving EGFR-tyrosine kinase inhibitors. Found CSD was inversely associated with PFS in a dose-dependent manner.

20. Results suggest that mutational activation of epidermal growth factor receptor (EGFR) inhibits major histocompatibility complex class I (MHC-I) expression through the MEK-ERK pathway in non-small cell lung cancer (NSCLC).

Mouse (Murine) Epidermal Growth Factor Receptor (EGFR) interaction partners

1. Gene deletion of Egfr in myeloid cells limits IL-6 and TNF-alpha production, lipid uptake, and consecutively reduces atherosclerosis development.

2. Our results identify a key role for NRG1/ErbB signalling in the regulation of hippocampal mGluRI-dependent synaptic and cognitive functions, whose alteration might contribute to the pathogenesis of different brain diseases.

3. Amphiregulin plays an important role in promoting cardiac fibrosis after myocardial infarction partly though activating the EGFR pathway.

4. We further show that EGFR is activated through toll-like receptor 4. Disruption of toll-like receptor 4 or the EGFR pathway led to reduced inflammatory activity and foam cell formation

5. HER2 and HER3 expression was detected in 22.2% and 86.1% of samples, respectively. The frequency of EGFR mutation was 45.7% and was not significantly different between stage 0 and IA1 (40.0% and 48.0%, respectively), suggesting that EGFR mutation does not correlate with cancer progression from stage 0 to IA1.

6. The results indicate that EGFR and its activation are critical for YAP-mediated suppression of TGF-beta1-induced apoptosis. This study provides a new understanding of the regulatory mechanism underlying the determination of cell fate in response to TGF-beta1-mediated simultaneous apoptosis and epithelial mesenchymal transformation.

7. our findings suggested the concept of the EGFR activated Osteoarthritis (OA) subpopulation and illustrated the mechanism of EGFR signaling in regulating cartilage homeostasis. Gefitinib could be a promising disease-modifying drug for this OA subpopulation treatment.

8. Cortactin expression in carcinoma cells and its known involvement in the EGFR pathway suggest a role for this protein as a target for laryngeal squamous cell carcinoma therapy.

9. results suggest ADAM17/EGFR-driven PLCgamma1 and PKC pathways as important promoters of TG1 expression during terminal keratinocyte differentiation.

10. Suggest caution for the proposed therapeutic strategy of combined signal transducer and activator of transcription/epidermal growth factor receptor inhibition for cancer treatment with respect to cardiotoxity.

11. Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocation.

12. miR-145 can decrease MUC5AC expression by inhibiting EGFR and alleviating airway remodeling. This indicates that miR-145 may be used as a molecular predictor for airway remodeling.

13. To evaluate the role of EGFR signaling in the articular cartilage, we studied a cartilage-specific Egfr-deficient (CKO) mouse model (Col2-Cre EgfrWa5/flox). These mice developed early cartilage degeneration at 6 mo of age. By 2 mo of age, although their gross cartilage morphology appears normal, CKO mice had a drastically reduced number of superficial chondrocytes and decreased lubricant secretion at the surface.

14. All these findings suggest that EGCG can resist skin senility effectively. And the EGFR with relate of downstream proteins are implicated in the skin aging.

15. Using a murine model for glioblastoma driven by a single genetic driver, the study suggests differences in EGFR activation contribute to tumor heterogeneity and aggressiveness.

16. These results suggest that EphA2/Efna1/Egfr genes, linked to a possible control by miR-200a and miR-26b, could be proposed as novel CRC prognostic biomarkers. Moreover, EphA2 could be linked to a mechanism of resistance to cetuximab alternative to KRAS mutations.

17. These results collectively suggest that sustained activation of Wnt/beta-catenin signaling in endothelial cells might be a cause of heart failure through suppressing neuregulin-ErbB signaling.

18. Epidermal growth factor receptor (EGFR) signaling enhances miR-29 expression in glioblastoma cells via upregulation of Sterol regulatory element binding protein 1

19. YAP accumulated in nuclei of mammary glands in ErbB2/EGFR-transgenic mice, suggesting that EGFR signaling affects YAP in vivo similar to cell culture. ErbB2/EGFR-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice.

20. Findings suggest that sEGFR might be a biomarker for evaluating insulin resistance or a therapeutic target of liraglutide.

Pig (Porcine) Epidermal Growth Factor Receptor (EGFR) interaction partners

1. this study shows that anemonin may ameliorate LPS-induced intestinal injury and improve restoration by regulating the TGF-b1 and EGFR signaling pathways

2. Syndecan-4 mediates porcine respiratory and reproductive syndrome virus entry by interacting with EGFR.

3. These results indicate that cAMP and oocyte-secreted factors cooperate to promote EGF receptor functionality in developing cumulus oocyte complexes, representing a key component of the acquisition of oocyte developmental competence.

4. patients experiencing gefitinib dose reduction or short-term treatment interruption due to toxicities did not show inferior survival, compared to those receiving full dose of gefitinib in non-small cell lung cancer patients with EGFR mutation

5. Report EGFR expression in the normal pancreas.

6. Injury and activation of purinergic receptors and direct activation of EGFR via EGF induce distinct downstream pathways.

7. Data suggest that the mechanism of hypoxia-induced increased activation of EGFR kinase is mediated by nNOS-derived nitric oxide.

8. An expressed transition SNP was identified in Meishan and white composite swine breeds.

9. EGFR, VEGFR and FGFR are expressed in porcine oviduct and endometrium during the time of implantation [review]

10. the restricted presence of the functional full-size receptor to the epithelial layer indicates a specific role during early embryonic development, whereas truncated EGF-R forms may potentially regulate contractions and blood flow in the oviduct

11. The phase-related expression of EGF and EGFR in the endothelium of the uterine artery and its branches suggest the modulatory effect of EGF and its receptor on the uterine artery and the region supplying these vessels.

12. This result suggests that ubiquitination of the kinase-impaired receptor can mediate its internalization by the clathrin pathway.

13. A linear relationship of EGF/EGFR, PI3-kinase, MAPK and geminal vesicle breakdown, presents a relatively definitive mechanism of EGF-induced meiotic resumption of porcine oocyte.

14. mRNA expression of EGF receptor

15. EGFR activation, by PKC signal pathway, participates in FSH-induced porcine oocyte meiotic resumption.

16. 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism.

Cow (Bovine) Epidermal Growth Factor Receptor (EGFR) interaction partners

1. Stimulation of bovine oviduct epithelial cell EGFR with EGF (human recombinant EGF) alone or with EGF in postovulatory/follicular phases (not luteal phase) up-regulates phosphorylation of MAPKs; heat blocks effects of EGF on phosphorylation of MAPKs.

2. Expression of the erbB/HER receptor family in the bovine uterus during the sexual cycle and the relation of this family to serum sex steroids.

3. Regulation of the sperm EGFR by ouabain leads to initiation of the acrosome reaction.

4. EGFR may simultaneously activate c-Src and PI3K to amplify the oxytocin signaling to increase the output of PGF(2 alpha) in endometrial epithelial cells.

5. results indicate that arginase induction depends in part on epidermal growth factor (EGF) receptor activity, and that EGFR inhibitors may attenuate vascular remodeling without affecting nitric oxide release

6. Data suggest that epidermal growth factor (EGF) and EGF receptors are important paracrine and/or autocrine regulators of spermatogenesis in bovine.

7. MT1-MMP has a role in signaling events mediating EGFR transactivation

8. possible cooperative role of the EGF and HGF pathways and indicate that cross-talk between their respective receptors may modulate mammary gland development in the cow

9. EGFR is stimulated during capacitation via PKA activation. More activation induces the acrosome reaction, which is induced by GPCR via EGFR transactivation by a signaling pathway involving PKA, SRC & metalloproteinase & effectors PI3K, PLC & PKC.

Rabbit Epidermal Growth Factor Receptor (EGFR) interaction partners

1. These results show that MMP-2 activates the EGFR and triggers downstream signaling pathways increasing Reactive Oxygen Species formation and promoting vasoconstriction.